文献速递外周动脉疾病

西洛他唑用于股腘动脉外周动脉疾病腔内治疗后患者的疗效与安全性的系统评价与Meta分析

A Systematic Review and Meta-Analysis of Efficacy and Safety of Cilostazol Prescription in Patients With Femoropopliteal Peripheral Artery Disease After Endovascular Therapy.
PubMed 文献 · J Endovasc Ther · 2024-04-09

该系统评价与Meta分析纳入4项随机对照试验和8项观察性研究共4898例股腘动脉外周动脉疾病腔内治疗后患者,评估西洛他唑的疗效与安全性。结果显示西洛他唑与更高的初级通畅率、更低的支架内再狭窄、重复血运重建和血管再闭塞风险相关,并提高免于靶病变血运重建率、减少主要不良肢体事件,但截肢、主要不良心血管事件、全因死亡和大出血无显著差异。

要点

  • 西洛他唑与股腘动脉腔内治疗后更高初级通畅率相关(OR=1.67,95%CI 1.50-1.87)。
  • 西洛他唑与更低支架内再狭窄(OR=0.43)、重复血运重建(OR=0.43)和血管再闭塞(OR=0.59)风险相关。
  • 截肢、主要不良心血管事件、全因死亡和大出血并发症无显著差异。

核心结论

  • 股腘动脉病变腔内治疗后加用口服西洛他唑可提高初级通畅率、降低支架内再狭窄和血管再闭塞发生、减少主要不良肢体事件风险、降低重复血运重建需求并提高免于靶病变血运重建率。
  • 西洛他唑对截肢、主要不良心血管事件、全因死亡或大出血并发症无影响。
  • 这些发现提示西洛他唑可能是股腘动脉外周动脉疾病腔内治疗后一种潜在安全有效的辅助治疗。

研究设计与样本

  • 系统评价与Meta分析,检索截至2022年9月所有报告股腘动脉外周动脉疾病腔内治疗后西洛他唑结局的研究。
  • 共纳入4项随机对照试验和8项观察性研究,合计4898例患者。

主要发现

  • 西洛他唑与更高的初级通畅率相关(OR=1.67,95%CI 1.50-1.87,p<0.001,I2=33.2%)。
  • 西洛他唑与更低的支架内再狭窄风险相关(OR=0.43,95%CI 0.29-0.63,p<0.001,I2=37.6%)。
  • 西洛他唑与更低的重复血运重建风险相关(OR=0.43,95%CI 0.24-0.76,p<0.005,I2=27.4%)。
  • 西洛他唑与更低的血管再闭塞风险相关(OR=0.59,95%CI 0.38-0.93,p<0.05,I2=0%)。
  • 西洛他唑与更高的免于靶病变血运重建率相关(OR=2.19,95%CI 1.58-3.05,p<0.001,I2=0%),并与更低的主要不良肢体事件发生相关(OR=0.50,95%CI 0.29-0.85,p<0.05,I2=0%)。

关键数值与推荐

  • 亚组分析显示,在股腘动脉药物洗脱支架植入患者中西洛他唑治疗仍与更高的初级通畅率和更低的支架内再狭窄风险相关。
  • 截肢、主要不良心血管事件、全因死亡和大出血并发症无显著差异。

临床怎么用

  • 股腘动脉病变腔内治疗后,在抗血小板治疗基础上加用西洛他唑可显著改善初级通畅率,降低支架内再狭窄、重复血运重建、血管再闭塞和主要不良肢体事件发生率,同时提高免于靶病变血运重建率。
  • 股腘动脉病变同时使用药物洗脱支架联合西洛他唑可能产生协同抗狭窄效应。
  • 该治疗策略似乎不增加大出血事件或全因死亡风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study is to assess the efficacy and safety of cilostazol prescription in patients with femoropopliteal peripheral artery disease (PAD) after endovascular therapy (EVT). MATERIALS AND METHODS: We conducted a systematic review and meta-analysis of all studies reporting the outcomes of cilostazol after femoropopliteal EVT of PAD up to September 2022. Clinical outcomes of interest included primary patency, in-stent restenosis (ISR), vessel re-occlusion, freedom from target lesion revascularization (TLR), repeat revascularization, all-cause mortality, amputation, major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs), and bleeding complication. RESULTS: A total of 4 randomized controlled trials (RCTs) and 8 observational studies containing a total of 4898 patients met the inclusion criteria and were included in this systematic review and meta-analysis. We found that the use of cilostazol was associated with higher primary patency after femoropopliteal artery EVT (odds ratio [OR]=1.67, 95% confidence interval [CI]=1.50-1.87, p<0.001, I2=33.2%), a lower risk of ISR (OR=0.43, 95% CI=0.29-0.63, p<0.001, I2=37.6%), repeat revascularization (OR=0.43, 95% CI=0.24-0.76, p<0.005, I2=27.4%), and vessel re-occlusion (OR=0.59, 95% CI=0.38-0.93, p<0.05, I2=0%). There was an increase in freedom from TLR rate (OR=2.19, 95% CI=1.58-3.05, p<0.001, I2=0%), as well as a reduction in the occurrence of MALEs (OR=0.50, 95% CI=0.29-0.85, p<0.05, I2=0%). However, there was no significant difference in amputation, MACEs, all-cause mortality, and major bleeding complications. Subgroup analysis showed that cilostazol treatment in patients with femoropopliteal drug-eluting stents (DES) implantation remained associated with higher primary patency and a lower risk of ISR. CONCLUSIONS: After EVT of femoropopliteal artery lesions, additional oral cilostazol enhances primary patency, reduces the occurrences of ISR and vessel re-occlusion, diminishes the risks associated with MALEs, lowers the need for repeat revascularization, and increases freedom from TLR rates. However, it does not impact amputation, MACEs, all-cause mortality, or major bleeding complications. These findings suggest cilostazol as a potentially safe and effective adjunct therapy in patients with femoropopliteal PAD after EVT.Clinical ImpactAfter undergoing endovascular therapy (EVT) for femoropopliteal artery lesions, the addition of cilostazol to antiplatelet therapy can significantly improve primary patency, reducing the incidence of in-stent restenosis, repeat revascularization, vessel re-occlusion, and major adverse limb events while increasing freedom from target lesion revascularization rate. The simultaneous use of drug-eluting stents in the femoropopliteal artery lesions, combined with cilostazol, potentially results in a synergistic anti-stenotic effect. This therapeutic approach does not appear to be associated with an increased risk of major bleeding events or all-cause mortality. These findings provide additional evidence supporting the treatment of anti-stenosis in patients with femoropopliteal artery lesions after EVT.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Tan Q, Chen Z, Wu H, et al. A Systematic Review and Meta-Analysis of Efficacy and Safety of Cilostazol Prescription in Patients With Femoropopliteal Peripheral Artery Disease After Endovascular Therapy. J Endovasc Ther. 2024. PMID: 38590247. doi:10.1177/15266028241241248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。